[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Maravai Lifesciences Holdings, Inc. (MRVI) reported an insider purchase by its Chief Executive Officer and director, Bernd Brust. On 11/13/2025, Brust, through The Bernd Brust Management Trust, purchased 216,212 shares of Class A common stock in an open-market transaction coded "P". The weighted average purchase price was $3.25 per share, with individual trade prices ranging from $3.235 to $3.25. Following this transaction, the trust beneficially owned 466,771 shares of Class A common stock held indirectly, and an additional 2,000,000 shares were listed as held directly.

Insights

Equity Ownership & Insider Trading Analyst

MRVI CEO Bernd Brust reported a sizable open-market share purchase.

The filing shows that Maravai Lifesciences CEO and director Bernd Brust bought 216,212 shares of Class A common stock on 11/13/2025. The trade is coded "P", indicating an open-market or private purchase, at a weighted average price of $3.25 per share, with individual trades between $3.235 and $3.25. This increases the interests reported for The Bernd Brust Management Trust to 466,771 shares held indirectly.

The table also lists 2,000,000 shares of Class A common stock as beneficially owned directly. Altogether, the disclosure highlights a meaningful personal stake in MRVI by its Chief Executive Officer, but the economic impact on the company’s balance sheet is indirect because these are secondary-market purchases between shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brust Bernd

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/13/2025		P		216,212	A	$3.25(1)	466,771	I	The Bernd Brust Management Trust
Class A Common Stock								2,000,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.235 to $3.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Bernd Brust	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MRVI report for its CEO Bernd Brust?

Maravai Lifesciences Holdings, Inc. (MRVI) reported that CEO and director Bernd Brust, through The Bernd Brust Management Trust, purchased 216,212 shares of Class A common stock on 11/13/2025 in an open-market transaction coded "P".

At what price did the MRVI CEO purchase the 216,212 Class A shares?

The 216,212 MRVI Class A shares were bought at a weighted average price of $3.25 per share, with individual trades executed at prices ranging from $3.235 to $3.25.

How many MRVI shares does The Bernd Brust Management Trust beneficially own after the transaction?

After the reported purchase, The Bernd Brust Management Trust beneficially owned 466,771 shares of Maravai Lifesciences Class A common stock, reported as indirectly held.

How many MRVI shares are listed as directly owned by Bernd Brust?

The Form 4 reports an additional 2,000,000 shares of Maravai Lifesciences Class A common stock as beneficially owned directly by Bernd Brust.

What does the transaction code "P" mean in the MRVI Form 4 filing?

In this MRVI Form 4, the transaction code "P" indicates a purchase of securities, typically an open-market or private transaction for Class A common stock.

Is the reported MRVI insider transaction under a Rule 10b5-1 trading plan?

The form includes a checkbox for transactions under a Rule 10b5-1(c) trading plan, but the excerpt does not indicate that this specific transaction was made pursuant to such a plan.